STERIS - STE Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for STERIS in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" STE shares.
View STE analyst ratings or view top-rated stocks.

6 equities research analysts have issued 1 year price objectives for STERIS's shares. Their STE share price forecasts range from $210.00 to $275.00. On average, they expect the company's share price to reach $232.83 in the next year. This suggests a possible upside of 25.7% from the stock's current price.
View analysts price targets for STE or view top-rated stocks among Wall Street analysts.

STERIS's stock was trading at $184.69 at the start of the year. Since then, STE shares have increased by 0.3% and is now trading at $185.20.
View the best growth stocks for 2023 here.

STERIS saw a decrease in short interest in February. As of February 28th, there was short interest totaling 2,400,000 shares, a decrease of 16.1% from the February 13th total of 2,860,000 shares. Based on an average trading volume of 546,700 shares, the short-interest ratio is currently 4.4 days. Approximately 2.4% of the company's shares are sold short.
View STERIS's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our STE earnings forecast.

STERIS plc (NYSE:STE) issued its quarterly earnings results on Wednesday, February, 8th. The medical equipment provider reported $2.02 EPS for the quarter, missing the consensus estimate of $2.19 by $0.17. The medical equipment provider earned $1.22 billion during the quarter, compared to analyst estimates of $1.27 billion. STERIS had a positive trailing twelve-month return on equity of 12.86% and a negative net margin of 0.58%. The firm's revenue was up .8% on a year-over-year basis. During the same period last year, the company earned $2.12 EPS.
Read the conference call transcript.

STERIS declared a quarterly dividend on Wednesday, February 1st. Investors of record on Friday, February 24th will be paid a dividend of $0.47 per share on Thursday, March 23rd. This represents a $1.88 dividend on an annualized basis and a yield of 1.02%. The ex-dividend date of this dividend is Thursday, February 23rd.
Read our dividend analysis for STE.

ETFs with the largest weight of STERIS (NYSE:STE) stock in their portfolio include VanEck Environmental Services ETF (EVX), VictoryShares THB Mid Cap ESG ETF (MDCP), First Trust Indxx Medical Devices ETF (MDEV), iShares U.S. Medical Devices ETF (IHI), Nuveen ESG Mid-Cap Value ETF (NUMV), BlackRock Future Health ETF (BMED), Invesco S&P 500 Equal Weight Health Care ETF (RYH) and SPDR S&P Health Care Equipment ETF (XHE).

STERIS (NYSE:STE) pays an annual dividend of $1.88 per share and currently has a dividend yield of 1.04%.
Read our dividend analysis for STE.

STERIS updated its FY 2023 earnings guidance on Wednesday, February, 8th. The company provided earnings per share guidance of $8.00-$8.10 for the period, compared to the consensus estimate of $8.43. The company issued revenue guidance of $4.86 billion-$4.86 billion, compared to the consensus revenue estimate of $4.94 billion.

196 employees have rated STERIS Chief Executive Officer Walter M. Rosebrough, Jr. on Glassdoor.com. Walter M. Rosebrough, Jr. has an approval rating of 79% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other STERIS investors own include Johnson & Johnson (JNJ), Home Depot (HD), AT&T (T), Visa (V), AbbVie (ABBV), Abbott Laboratories (ABT), Pfizer (PFE), Gilead Sciences (GILD), Mastercard (MA) and Medtronic (MDT).

STERIS trades on the New York Stock Exchange (NYSE) under the ticker symbol "STE."

STERIS's stock is owned by a variety of retail and institutional investors. Top institutional investors include WCM Investment Management LLC (5.57%), Morgan Stanley (3.78%), Price T Rowe Associates Inc. MD (2.38%), Geode Capital Management LLC (2.13%), Alliancebernstein L.P. (1.62%) and Select Equity Group L.P. (1.54%). Insiders that own company stock include Cary L Majors, Cary L Majors, Cynthia L Feldmann, Daniel A Carestio, David B Lewis, Jacqueline B Kosecoff, John Adam Zangerle, Julia Madsen, Karen L Burton, Michael J Tokich, Mohsen Sohi, Renato Tamaro, Richard C Breeden and Walter M Rosebrough Jr.
View institutional ownership trends.

Shares of STE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of STE stock can currently be purchased for approximately $185.20.

STERIS (NYSE:STE) has a market capitalization of $18.39 billion and generates $4.59 billion in revenue each year. The medical equipment provider earns $243.89 million in net income (profit) each year or ($0.29) on an earnings per share basis.

The company employs 16,422 workers across the globe.

STERIS's mailing address is 70 Sir John Rogerson`s Quay, Dublin L2, D02 R296. The official website for the company is www.steris.com. The medical equipment provider can be reached via phone at (440) 354-2600, via email at julie_winter@steris.com, or via fax at 440-639-4457.